Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
aripiprazole
- Development stage
- Approved
- Lead developer
- Taiho Pharmaceutical
- Modality
- Small Molecules
- Administration
- Intramuscular, Oral
01
Overview
Aripiprazole is an atypical antipsychotic (second-generation antipsychotic) used to treat a range of psychiatric disorders, including schizophrenia, bipolar I disorder, major depressive disorder (as adjunctive therapy), irritability associated with autism spectrum disorder, and Tourette's syndrome. It acts as a partial agonist at dopamine D2 and serotonin 5‑HT1A receptors and as an antagonist at serotonin 5‑HT2A receptors. This unique mechanism is thought to stabilize dopamine and serotonin activity in the brain, improving symptoms of psychosis, mood disturbances, and behavioral dysregulation. Aripiprazole was originally developed by Otsuka Pharmaceutical[5][6].
- Brand names
- AbilifyAbilify MaintenaAristadaAbilify AsimtufiiMezofyOpipzaAbilify DiscmeltAbilify Mycite
- Other names
- Aripiprazolum
02
Targets
HTR2A (Serotonin receptor 5-HT2A)SERT (Sodium-dependent serotonin transporter)HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))HTR2C (5-hydroxytryptamine 2C receptor)HRH1 (Histamine H1 Receptor)ADRA1A (α1A)HTR2B (5-Hydroxytryptamine Receptor 2B)DRD2 (Dopamine D2 Receptor)HTR7 (5-hydroxytryptamine receptor 7)DRD3 (Dopamine receptor D3)
Beyond the preview
Go deeper on aripiprazole.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on aripiprazole.